CoChat

Atenolol in hypertension: is it a wise choice?

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Background Atenolol is one of the most widely used beta blockers clinically, and has often been used as a reference drug in randomised controlled trials of hypertension. However, questions have been raised about atenolol as the best reference drug for comparisons with other antihypertensives. Thus, our aim was to systematically review the effect of atenolol on cardiovascular morbidity and mortality in hypertensive patients. Methods Reports were identified through searches of The Cochrane Library, MEDLINE, relevant textbooks, and by personal communication with established researchers in hypertension. Randomised controlled trials that assessed the effect of atenolol on cardiovascular morbidity or mortality in patients with primary hypertension were included. Findings We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with other antihypertensive drugs. Despite major differences in blood pressure lowering, there were no outcome differences between atenolol and placebo in the four studies, comprising 6825 patients, who were followed up for a mean of 4.6 years on all-cause mortality (relative risk 1.01 [95% CI 0.89-1.15]), cardiovascular mortality (0.99 [0.83-1.18]), or myocardial infarction (0.99 [0.83-1.19]). The risk of stroke, however, tended to be lower in the atenolol than in the placebo group (0.85 [0.72-1.01]). When atenolol was compared with other antihypertensives, there were no major differences in blood pressu…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)17355-8

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

See all 562

Metadata

Authors
Carlberg, B., Samuelsson, O., & Lindholm, L. H.
Affiliations
  • University Hospital of Umeå (SE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Lindholm, Lars Hjalmar
Venue
The Lancet
Publisher
Elsevier BV
Published
2004-11
Volume
364
Issue
9446
Pages
1684-1689
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2029436713
Cited by
562
References
43
Citations by year
2026: 2 · 2025: 6 · 2024: 16 · 2023: 12 · 2022: 12 · 2021: 9 · 2020: 22 · 2019: 9 · 2018: 18 · 2017: 19 · 2016: 19 · 2015: 12 · 2014: 26 · 2013: 22 · 2012: 26
FWCI
10.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
atenolol, beta-blockers, hypertension, essential hypertension, cardiovascular mortality, all-cause mortality, myocardial infarction, stroke, reference drugs, antihypertensive drugs, blood pressure reduction, cardiovascular morbidity
MeSH terms
Adrenergic beta-Antagonists, Antihypertensive Agents, Atenolol, Blood Pressure, Humans, Hypertension, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atenolol in hypertension: is it a wise choice? https://app.cochat.ai/papers/10.1016/s0140-6736(04)17355-8
The paper
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004). Atenolol in hypertension: is it a wise choice? The Lancet. https://doi.org/10.1016/s0140-6736(04)17355-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.